Plasma clusterin increased prior to Small for Gestational Age (SGA) associated with preeclampsia and decreased prior to SGA in normotensive pregnancies

Reproductive Sciences

Volumn 19, Issue 6, 2012, Pages 650-657

  Blumenstein, Marion ^a   McCowan, Lesley M E ^b   Wu, Steven ^a   Cooper, Garth J S ^a,c,d   North, Robyn A ^b,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

clusterin; difference in gel electrophoresis; DIGE; plasma; preeclampsia; small for gestational age

Indexed keywords

CLUSTERIN;

ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; GESTATIONAL AGE; HUMAN; NULLIPARA; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; SMALL FOR DATE INFANT;

ADULT; BIOLOGICAL MARKERS; CLUSTERIN; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDIES;

EID: 84862834214     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719111430999     Document Type: Article

References (30)

1. McCormick MC. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med. 1985 ; 312 (2). 82-90 (Pubitemid 15192138)
2. McCowan LME, Roberts CT, Dekker GA, et al. SCOPE consortium. Risk factors for small-for-gestational-age infants by customized birthweight centiles: data from an international prospective cohort study. Br J Obstet Gynaecol. 2010 ; 117 (13). 1599-1607
3. Groom KM, North RA, Poppe KK, Sadler L, McCowan LM. The association between customized small for gestational age infants and pre-eclampsia or gestational hypertension varies with gestation at delivery. Br J Obstet Gynaecol. 2007 ; 114 (4). 478-484 (Pubitemid 46393307)
4. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005 ; 308 (5728). 1592-1594 (Pubitemid 40807500)
5. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006 ; 195 (1). 40-49 (Pubitemid 43927490)
6. Shankar R, Gude N, Cullinane F, Brennecke S, Purcell AW, Moses EK. An emerging role for comprehensive proteome analysis in human pregnancy research. Reproduction. 2005 ; 129 (6). 685-696 (Pubitemid 40872820)
7. Blumenstein M, McMaster MT, Black MA, et al. A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics. 2009 ; 9 (11). 2929-2945
8. Watanabe H, Hamada H, Yamada N, et al. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics. 2004 ; 4 (2). 537-543 (Pubitemid 38235273)
9. Blankley RT, Gaskell SJ, Whetton AD, Dive C, Baker PN, Myers JE. A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia. Br J Obstet Gynaecol. 2009 ; 116 (11). 1473-1480
10. Auer J, Camoin L, Guillonneau F, et al. Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J Proteomics. 2010 ; 73 (5). 1004-1017
11. Jenne DE, Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci. 1992 ; 17 (4). 154-159
12. McCowanLNorthRTaylorR. ACTRN12607000551493. Australian New Zealand Clinical Trials Registry, 2007. www.anzctr.org.au/trialSearch.aspx.
13. Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. Ultrasound Obstet Gynecol. 1995 ; 6 (3). 168-174
14. North RA, McCowan LM, Dekker GA, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011 ; 342: d1875
15. Shin JK, Han KA, Kang MY, et al. Expression of clusterin in normal and preeclamptic placentas. J Obstet Gynaecol Res. 2008 ; 34 (4). 473-479
16. Witte DP, Aronow BJ, Stauderman ML, et al. Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am J Pathol. 1993 ; 143 (3). 763-773 (Pubitemid 24058232)
17. Chen M, Yuan Z, Shan K. Association of apolipoprotein J gene 866C - >T polymorphism with preeclampsia and essential hypertension. Gynecol Obstet Invest. 2005 ; 60 (3). 133-138 (Pubitemid 41433924)
18. Bartl MM, Luckenbach T, Bergner O, Ullrich O, Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp Cell Res. 2001 ; 271 (1). 130-141 (Pubitemid 33071000)
19. Santilli G, Aronow BJ, Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem. 2003 ; 278 (40). 38214-38219 (Pubitemid 37221710)
20. Schwarz M, Spath L, Lux CA, et al. Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity. Thromb Haemost. 2008 ; 100 (1). 110-118 (Pubitemid 351948752)
21. Sivamurthy N, Stone DH, Logerfo FW, Quist WC. Apolipoprotein J inhibits the migration, adhesion, and proliferation of vascular smooth muscle cells. J Vasc Surg. 2001 ; 34 (4). 716-723 (Pubitemid 33664924)
22. Trougakos IP, Djeu JY, Gonos ES, Boothman DA. Advances and challenges in basic and translational research on clusterin. Cancer Res. 2009 ; 69 (2). 403-406
23. Kapron JT, Hilliard GM, Lakins JN, et al. Identification and characterization of glycosylation sites in human serum clusterin. Protein Sci. 1997 ; 6 (10). 2120-2133 (Pubitemid 27449292)
24. Cochrane DR, Wang Z, Muramaki M, Gleave ME, Nelson CC. Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem. 2007 ; 282 (4). 2278-2287 (Pubitemid 47076744)
25. Hellebrekers DM, Melotte V, Vire E, et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 2007 ; 67 (9). 4138-4148 (Pubitemid 46815059)
26. Jackson JK, Gleave ME, Gleave J, Burt HM. The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis. 2005 ; 8 (3). 229-238 (Pubitemid 41759147)
27. Stewart EM, Aquilina JA, Easterbrook-Smith SB, et al. Effects of glycosylation on the structure and function of the extracellular chaperone clusterin. Biochemistry. 2007 ; 46 (5). 1412-1422 (Pubitemid 46208489)
28. Arkwright PD, Redman CW, Williams PJ, Dwek RA, Rademacher TW. Syncytiotrophoblast membrane protein glycosylation patterns in normal human pregnancy and changes with gestational age and parturition. Placenta. 1991 ; 12 (6). 637-651
29. Karamessinis PM, Malamitsi-Puchner A, Boutsikou T, et al. Marked defects in the expression and glycosylation of alpha2-HS glycoprotein/fetuin-A in plasma from neonates with intrauterine growth restriction: proteomics screening and potential clinical implications. Mol Cell Proteomics. 2008 ; 7 (3). 591-599 (Pubitemid 351472468)
30. Rodriguez-Pineiro AM, de la Cadena MP, Lopez-Saco A, Rodriguez-Berrocal FJ. Differential expression of serum clusterin isoforms in colorectal cancer. Mol Cell Proteomics. 2006 ; 5 (9). 1647-1657 (Pubitemid 44480392)